Skip to main content
Premium Trial:

Request an Annual Quote

GMU Proteomics Partners with Virginia Clinic on Myeloma Study

NEW YORK (GenomeWeb News) – Cancer and proteomics scientists at George Mason University have created a partnership with Fairfax-Northern Virginia Hematology Oncology in a privately-funded program aimed at finding the protein signal pathways involved in multiple myeloma.
The University’s Center for Applied Proteomics and Molecular Medicine will use funding from the Chris Walker Multiple Myeloma Foundation to work with the Fairfax clinic to study the effects of experimental treatments on living tumor cells from multiple myeloma patients.
The goal is to try to use the pathways analysis to develop novel therapeutic targets for treatments of a blood cancer that, according to the Multiple Myeloma Research Foundation, will be diagnosed in nearly 20,000 people in 2008. 
"This novel trial will test a large series of targeted inhibitors, alone and in unique combinations, which block key signaling pathways in the tumor cells,” CAPMM Co-director Lance Liotta said in a statement. “This is a key first step toward true individualized therapy for multiple myeloma."

The Scan

Alzheimer's Risk Gene Among Women

CNN reports that researchers have found that variants in MGMT contribute to Alzheimer's disease risk among women but not men.

Still Hanging Around

The Guardian writes that persistent pockets of SARS-CoV-2 in the body could contribute to long COVID.

Through a Little Spit

Enteric viruses like norovirus may also be transmitted through saliva, not just the fecal-oral route, according to New Scientist.

Nature Papers Present Method to Detect Full Transcriptome, Viruses Infecting Asgard Archaea, More

In Nature this week: VASA-seq approach to detect full transcriptome, analysis of viruses infecting Asgard archaea, and more.